GSK: cross-border access for the specialty portfolio

Quick orientation

GSK plc (formerly GlaxoSmithKline) is a UK-headquartered biopharmaceutical company based in Brentford, London, with US operations in Philadelphia and Research Triangle Park, North Carolina. GSK separated its consumer health business as Haleon in 2022 to focus on innovative medicines and vaccines. The specialty footprint is anchored in respiratory immunology (Nucala in severe eosinophilic asthma and EGPA; Trelegy in COPD), immunology (Benlysta in SLE and lupus nephritis), oncology (Jemperli in endometrial cancer; Zejula in ovarian cancer; Blenrep restricted in multiple myeloma), HIV (the joint-venture ViiV Healthcare portfolio Tivicay, Dovato, Cabenuva), and vaccines (Shingrix, Arexvy in adult RSV, the Bexsero meningococcal franchise).

Portfolio in cross-border NPP scope

Nucala (mepolizumab)

Anti-IL-5 monoclonal antibody approved for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps. International requests cluster around EGPA patients in MENA and India where the locally registered indications are limited to severe asthma, and around HES patients where no other on-label option exists.

Benlysta (belimumab)

Anti-BLyS monoclonal antibody approved for systemic lupus erythematosus and active lupus nephritis. International requests come from lupus nephritis patients in MENA and India where the lupus nephritis indication has not yet been added locally, and from pediatric SLE patients (the pediatric indication is newer).

Jemperli (dostarlimab)

PD-1 inhibitor approved for primary advanced or recurrent endometrial cancer in combination with carboplatin and paclitaxel, with extended labeling in mismatch-repair-deficient solid tumors. International requests come from endometrial cancer patients in MENA and India where the combination first-line indication has not been added locally despite the strong overall-survival data.

Zejula (niraparib)

PARP inhibitor approved for maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. International requests come from ovarian cancer patients in MENA and India where the locally available PARP options are restricted to olaparib only.

Blenrep (belantamab mafodotin)

BCMA-directed antibody-drug conjugate. In late 2025 and 2026 Blenrep has new combination approvals in relapsed multiple myeloma after positive DREAMM-7 and DREAMM-8 data. International requests come from triple-class refractory myeloma patients in MENA and India where the new combinations have not yet been added locally.

Trelegy Ellipta

Triple-therapy fixed-dose combination of fluticasone furoate, umeclidinium, and vilanterol for COPD and asthma in adults. Cross-border requests come from patients in MENA and India who prefer the single-inhaler triple-therapy over separate inhalers, and where the asthma indication has not been added locally.

Arexvy

Adjuvanted respiratory syncytial virus vaccine approved for prevention of RSV lower respiratory tract disease in adults 50 and older, including adults at increased risk. International requests come from older adults in MENA and the Gulf seeking the adult RSV vaccine where it is not yet locally registered.

Shingrix

Adjuvanted recombinant zoster vaccine for prevention of herpes zoster in adults 50 and older, and in immunocompromised adults 18 and older. International requests come from immunocompromised patients in MENA and India seeking adequate herpes zoster prophylaxis.

ViiV HIV portfolio (Tivicay, Dovato, Cabenuva)

The GSK-Pfizer-Shionogi joint venture ViiV Healthcare carries the HIV franchise. Cross-border requests focus on Cabenuva (the long-acting injectable cabotegravir-rilpivirine combination) where the locally available HIV regimens remain oral-only.

Why patients route GSK products through cross-border NPP

Three patterns dominate. First, the IL-5 respiratory and eosinophilic franchise (Nucala) carries indication-expansion gaps for EGPA, HES, and CRSwNP where local labels lag the US.

Second, the oncology franchise (Jemperli endometrial first-line combination, Zejula maintenance ovarian, Blenrep myeloma combinations) is in active indication expansion, and MENA and India payer formularies have not caught up.

Third, the GSK Patient Access Program is restricted to US residents. International patients route as cash-pay.

Manufacturer engagement posture

Reserve Meds coordinates GSK and ViiV-manufactured US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized GSK distributor; we are an independent named-patient program coordinator. Patient assistance program coverage does not extend to cross-border patients. All Reserve Meds orders are cash-pay at firm-quote pricing.

For GSK and ViiV market access, medical affairs, and international new product planning teams: Reserve Meds maintains structured demand visibility across the eosinophilic respiratory, oncology, lupus, and HIV franchises. If your group is sizing pre-registration demand in MENA and India, we are open to a structured conversation under NDA.

Common cross-border destinations for the GSK portfolio

The respiratory and immunology franchise (Nucala, Benlysta, Trelegy) concentrates in the UAE, Saudi Arabia, India, and Egypt. The oncology franchise (Jemperli, Zejula, Blenrep) tracks oncology specialist concentration in India, Saudi Arabia, Egypt, and the UAE. The adult vaccine franchise (Shingrix, Arexvy) is heaviest in the Gulf for older adult populations.

What Reserve Meds provides

For every GSK product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required (Nucala, Benlysta, Jemperli, Blenrep, Cabenuva, all vaccines); country regulatory pathway expertise covering named-patient import approval; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a GSK product and want a firm quote can start a request below.

Start a request for a GSK product

Next step for GSK teams

If you are on the GSK or ViiV access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.